Acasti Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACST.V research report →
Companywww.acastipharma.com
Acasti Pharma Inc. , a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre.
- CEO
- Janelle D'Alvise
- IPO
- 2011
- HQ
- Laval, QC, CA
Price Chart
Valuation
- Market Cap
- $25.88M
- P/E
- -5.43
- P/S
- 0.00
- P/B
- 0.57
- EV/EBITDA
- -1.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -10.61%
- ROIC
- -15.75%
Growth & Income
- Revenue
- $14.25M · -22.76%
- Net Income
- $-64,915,000 · 14.21%
- EPS
- $-0.99 · 56.96%
- Op Income
- $-73,155,000
- FCF YoY
- 68.17%
Performance & Tape
- 52W High
- $1.51
- 52W Low
- $0.47
- 50D MA
- $0.81
- 200D MA
- $0.87
- Beta
- 1.22
- Avg Volume
- 4.98K
Get TickerSpark's AI analysis on ACST.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACST.V Coverage
We haven't published any research on ACST.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACST.V Report →